{"title":"Future oral drug options for multiple sclerosis treatment","authors":"Carolyn Young MD, FRCP","doi":"10.1002/fps.69","DOIUrl":null,"url":null,"abstract":"<p><b>Multiple sclerosis is a common, chronic and disabling neurological disease with a variable clinical course including relapse and progression. Here the author reviews three promising oral agents, currently in the late stages of development and regulatory approval, for the treatment of MS that appear to reduce the frequency of relapses and improve patient acceptability.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"11 3","pages":"12-15"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.69","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.69","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Multiple sclerosis is a common, chronic and disabling neurological disease with a variable clinical course including relapse and progression. Here the author reviews three promising oral agents, currently in the late stages of development and regulatory approval, for the treatment of MS that appear to reduce the frequency of relapses and improve patient acceptability.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
